79 related articles for article (PubMed ID: 2195445)
21. [Multicenter study of the antibacterial activity of a new cephalosporin: CM 40874].
Duval J; Soussy CJ; Deforges L; Brun Y; Coulet M; Forey F; Thabaut A; Meyran M; Acar JF; Kitzis MD
Pathol Biol (Paris); 1984 May; 32(5):331-4. PubMed ID: 6547524
[TBL] [Abstract][Full Text] [Related]
22. [In vitro activity of roxithromycin against hospital bacteria and the concordance curve].
Soussy CJ; Chanal M; Kitzis MD; Duval J; Cluzel R; Acar JF
Pathol Biol (Paris); 1988 May; 36(5):420-4. PubMed ID: 2900488
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial activity of cefpodoxime in vitro.
Liu YC; Huang WK; Cheng DL
Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
[TBL] [Abstract][Full Text] [Related]
24. In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin.
Chin NX; Neu HC
Chemioterapia; 1987 Oct; 6(5):329-36. PubMed ID: 3322588
[TBL] [Abstract][Full Text] [Related]
25. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages.
Yokota T; Suzuki E; Arai K
Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
Sheppard M; King A; Phillips I
Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):573-81. PubMed ID: 1915400
[TBL] [Abstract][Full Text] [Related]
27. [In vitro antibacterial activity of a new fluoroquinolone, fleroxacin, against hospital bacteria and regression curve].
Soussy CJ; Cluzel M; Derlot E; Kitzis MD; Meyran M
Pathol Biol (Paris); 1994 May; 42(5):385-92. PubMed ID: 7824301
[TBL] [Abstract][Full Text] [Related]
28. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
Wallrauch-Schwarz C; Milatovic D; Braveny I
Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
[TBL] [Abstract][Full Text] [Related]
29. [In vitro effect of ceftriaxone on hospital bacteria. Line of regression and critical values].
Cluzel M; Chanal M; Sirot D; Sirot J; Cluzel R
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):473-6. PubMed ID: 3937122
[TBL] [Abstract][Full Text] [Related]
30. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
31. [In vitro activity of imipenem against hospital bacteria].
Soussy CJ; Duval J
Presse Med; 1990 Apr; 19(13):583-7. PubMed ID: 2139936
[TBL] [Abstract][Full Text] [Related]
32. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
Caisson A; Chantot JF
Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
[TBL] [Abstract][Full Text] [Related]
33. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of LY164846, a new oral cephalosporin, and recommendations for disk diffusion tests.
Sassine-Nawas G; Baker CN; Thornsberry C
Diagn Microbiol Infect Dis; 1987 Jan; 6(1):41-8. PubMed ID: 3100126
[TBL] [Abstract][Full Text] [Related]
35. The in-vitro activity of cefodizime: a review.
Soussy CJ; Chanal M; Kitzis MD
J Antimicrob Chemother; 1990 Nov; 26 Suppl C():13-21. PubMed ID: 2074248
[TBL] [Abstract][Full Text] [Related]
36. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
Jones RN; Zurenko GE
Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
Wiedemann B; Luhmer E; Zühlsdorf MT
Infection; 1991; 19(5):363-9. PubMed ID: 1800378
[TBL] [Abstract][Full Text] [Related]
39. Microbiological evaluation of cefpodoxime proxetil.
Wiedemann B; Luhmer E; Zühlsdorf MT
Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
[TBL] [Abstract][Full Text] [Related]
40. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases.
Cullmann W; Dick W
Zentralbl Bakteriol; 1990 Sep; 273(4):501-17. PubMed ID: 2248685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
